filed 6/25/04 Sheet 1 of 1

Form 1	PTO	-14	49							ment of Commerce Trademark Office	Atty. Docket N 2609/60807-A JPW/GJG/DJ	No. A-PCT-US	Serial No. 10/792,311		
INFOI (Use se									CITA	TION	Applicants Alexander Gad	l and Dora Lis			
USE SE	evera	5	nee			ece:		y) 			Filing Date March 2, 2	004	Group 1644		
U.S. P	ATE	NT	D	<u>oc</u>	UM	1EI	NTS	S .						•	
Examin								·	Date	Name	Class .	Subclass	Filing Date if Appropria	ite	
nitial PJ#	· .	20	04	0	6	0	2	2	1/8/04	Strominger, et al.					
'															
FORE	IGN	PA	ATE	EN	ΓD	000	CUN	MEN	NTS						
		Γ							Date	Country	Class	Subclass	Translati	ion	
.													Yes	No	
				Ė		Τ	Π	Π							
		T	1			T	<u> </u>					-	*		
		╁	\vdash	-	┢	T	╁╌	t					 		
		\vdash	H	H	┢	t	-	\vdash					<u> </u>		
		十	┢	┢	 	╁	-	╁							
		╁╌	╁	╁	╁	╁	├	\vdash			-				
		├	-	-	┢	+	\vdash	├							
		\vdash	-	╁	-	╁	-	-							
		┢	╁	╀	-		╂	-	}	<u> </u>	 				
			<u> </u>	<u> </u>	<u> </u>	<u> </u>	느	<u> </u>	1	J.,		1	<u> </u>		
OTHER	R DO	CU.	ME	NTS	S (Ir	<u>ıclu</u>	ding	Aut	hor, Title	e, Date, Pertinent Pages,	Etc.)		•		
		\vdash											·		
		╀								·					
		_													
		1													
		_						0					12		
	ļ												**********	•	
	<u> </u>														
		L							7						
										****		3			
										·					
		Τ									•				
EXAM	INER		٦.		1				DATE C	CONSIDERED					
*EVAM	NED	Ini	ial if	cité	ion	cone	idere	d who	ether or not	citation is in conformance win	th MPEP 609: Drav	w line through ci	tation if not in o	conformance :	

filed 3/2/04

Page 1 of 16 Serial No. Atty. Docket No. **U.S. Department of Commerce** Form PTO-1449 60807-AA-PCT-US/ Not Yet Known Patent and Trademark Office IPW/ GJG/DJK 10/7923 INFORMATION DISCLOSURE CITATION Applicants: Alexander Gad and Dora Lis (Use several sheets if necessary) Group Art Unit Filing Date Herewith U.S. PATENT DOCUMENTS Name Class Subclass Filing Date Document Number Date Examiner if Appropriate Initial 11/19/74 Teitelbaum, et al. PUH 11/09/76 Shea Ю 7/13/82 Gaffar 4/20/93 Barbier, et al. Ю 9/10/96 Hunter et al. 12/10/96 Stern 1/7/97 Rodriguez, et al. 4/22/97 McLean et al. 5/6/97 Hupe, et al. 6 2 9/16/97 Shapiro, et al. 2/17/98 Acton, et al. FOREIGN PATENT DOCUMENTS Translation Subclass Class Country Document Number Date Yes wo 12/29/88 US wo 2/20/92 Europe wo 2/17/94 บร 11/24/94 US พด b US wo 2 Ю 10/12/95 US wo 11/30/95 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Abramsky, et al., "Effect of a Synthetic Polypeptide (COP-1) on Patients with Multiple Sclerosis and with Acute Disseminated Encephalomyelitis", J. Neurol. Sci., 1977, 31, 433-438 Aharoni, et al., "T Suppressor Hybridomas and Interleukin-2-Dependent Lines Induced by Copolymer 1 or by Spinal Cord Homogenate Down-Regulate Experimental Allergic Encephalomyelitis", Eur. J. Immunol., 1993, <u>23</u>, 17-25; Aharoni, et al., "Studies on the Mechanism and Specificity of the Effect of the Synthetic Random Copolymer GLAT on Graft-versus-Host Disease", Immunol, Letters, 1997, 58, 79-87; Alvord, et al., "Myelin Basic Protein Treatment of Experimental Allergic Encephalomyelitis in Monkeys", Ann. Neurol., 1979, 6, 469-473 Arnon, et al., "Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Copolymer Immunological Cross Reactive with Basic Encephalitogen", Israel J. Med. Sci., 1972, 8, 1759-1760; DATE CONSIDERED EXAMINER EXAMINER: Ifitial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Page 2 of 16 Atty. Docket No. Serial No. Form PTO-1449 **U.S. Department of Commerce** 60807-AA-PCT-US/ Not Yet Known Patent and Trademark Office 10/792311 JPW/ GJG/DJK INFORMATION DISCLOSURE CITATION Applicants: Alexander Gad and Dora Lis (Use several sheets if necessary) Filing Date Group Art Unit Herewith **U.S. PATENT DOCUMENTS** Class Subclass Filing Date Date Name Document Number Examiner if Appropriate Initial 3/31/98 Bishwajit et al. 9/1/98 Konfino, et al. 0 1/12/99 Aharoni, et al. 3/23/99 McLean et al. 9/28/99 Hupe, et al. 11/9/99 Konfino, et al. 4/11/00 Konfino, et al. Ю 4/25/00 Konfino, et al. 0 4/10/01 Arnon, et al. 1/29/02 Konfino, et al. 3/26/02 Konfino, et al. FOREIGN PATENT DOCUMENTS Translation Class Subclass Document Number Date Country Yes 11/30/95 US wo wo 5 12/14/95 Europe 7/16/98 US wo 2/3/00 US wo 2/3/00 บร wo lus 4/6/00 wo OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Arnon, et al., "Suppression of EAE in Baboons by a Synthetic Polymer of Amino Acids", Neurol., 1978, 28, PNH 336 (Abstract); Arnon, et al., "Desensitization of Experimental Allergic Encephalomyelitis with Synthetic Peptide Analogues" in The Suppression of Experimental Allergic Encephalomyelitis and Multiple Sclerosis (Academic Press, New York, 1980) 105-107; Arnon, "A Synthetic Copolymer of Amino Acids in a Clinical Trial for MS Therapy" in Progress in Multiple Sclerosis Research (Bauer, Ritter, eds., Springer Verlag New York, 1980) 416-418; Arnon, "Experimental Allergic Encephalomyelitis - Susceptibility and Suppression", Immunological Rev., 1981, <u>55</u>, 5-30; Arnon, et al., "Suppression of Demyelinating Diseases by Synthetic Copolymers", in A Multidisciplinary Approach to Myelin Disease (G. Serlupi Crescenzi, ed., Plenum Publishing Corp., 1988) 243-250 DATE CONSIDERED EXAMINER EXAMINER: thitial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in

conformance and nor considered Include copy of this form with next communication to applicant.

Page 3 of 16 Serial No. Atty. Docket No. **U.S. Department of Commerce** Form PTO-1449 60807-AA-PCT-US/ Not Yet Known Patent and Trademark Office JPW/ GJG/DJK 1792.311 INFORMATION DISCLOSURE CITATION Applicants: Alexander Gad and Dora Lis (Use several sheets if necessary) Group Art, Unit Filing Date Herewith **U.S. PATENT DOCUMENTS** Filing Date Class Subclass Document Number Name Examiner if Appropriate Initial, 2/4/03 Gad et al. DNH 9/16/03 Konfino, et al. A1 12/27/01 Gilbert, et al. 20 01 00 55 56 8 20 02 00 37 84 8 A1 03/28/02 Eisenbach-Schwartz et al. 20 02 01 07 38 8 08/08/02 Vandenbark A1 8/22/02 20 |02 |01 |15 |10 |3 Gad, et al. Eisenbach-Schwartz et al. 01/02/03 20 | 03 | 00 | 04 | 09 | 9 ΑI 7/22/99 Strominger, et al. 09 09 8 1/20/00 lo 7/20/02 09 FOREIGN PATENT DOCUMENTS Translation Class Subclass Document Number Date Country Yes No 4/13/00 US wo US 5/18/00 wo US wo 7/26/01 wo 8/23/01 US wo 12/3/01 US wo 12/13/01 US OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Pending claims of U.S. Serial No. 09/816,989 (Gad et al.)(Item 28)., U.S. Patent Publication No. 20020115103 A1, for the Examiner's convenience Amon, et al., "Suppression of Experimental Allergic Encephalomyelitis by Cop-1 - Relevance to Multiple Sclerosis", Israel J. Med. Sci., 1989, 25, 686-689; Amon, et al., "Immunomodulation of Experimental Allergic Encephalomyelitis", Israel J. Med. Sci., 1993, 29, 175-181: Arnon, et al., "On the Existence of Suppressor Cells", Int. Arch. Allergy Immunol., 1993, 100, 2-7; Amon, et al., "Immunospecific Drug Design - Prospects for Treatment of Autoimmune Disease", Therapeutic

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

<u>Immunol.</u>, 1994, <u>1</u>, 65-70;

EXAMINER

Form PTC)-144	9		τ	J.S.	Dej	part:	men	nt of Comm	erce Tice	Atty. Doc		Serial N Not Yet	0.	
		-			rav	emt (anu	114	IGCIIMI K OI	nce	10000	JPW/ GJG/DJK (0/792,)			
		IN	FO						OSURE C		Applicant	Applicants: Alexander Gad and Dora			
				(Us	se se	ever	ai si	ieeu	s if necessar		Filing Date Herewith		Group Art Unit		
									U.S. PA	TENT DOCUMENTS					
Examiner Initial		Do	cun	ent	Nu	mbe	er		Date Name Class St		Subcláss	Subclass Filing Da			
< PYK		09	7	6	5	6	4	4				1			
1			8	7	5	4	2	9	6/5/01	Yong and Chabot					
V		09	8	8	5	<u> 2</u>	2	7	6/5/01	Rodriguez and Ure	·			_	
		┡	<u> </u>	1	╄	╄	₩	-		 			-		
	 	├	-	┼	┼	╁	1	╁	 	- 					
	-	-	-	╁╌	╁╴	+	+	\vdash	ļ				† · · · · ·		
	 -	╁	\vdash		\vdash	+	T		 						
												`			
				L	oxdot		L	oxdapprox							
	<u> </u>	<u> </u>	<u> </u>	_ـــــــــــــــــــــــــــــــــــــ	L	_	_	<u> </u>	<u> </u>			<u> </u>	<u> </u>		
									FOREIGN	PATENT DOCUMEN	TS		I.m. ii		
		Do	cun	nent	Nu	mb	er		Date	Country	Class	Subclass	Transl	Γ	
	<u> </u>												Yes	No	
Pult	wo	0	1	9	7	8	4	6	12/27/01	US					
1	EP	03	8	3	6	2	0	A2	8/22/90	Europe					
	EP	03	5	9	7	8	3	В1	11/29/95	Europe				<u> </u>	
			T	T	1	T		1							
	\dagger		╁	\dagger	十	╁	+	t	<u> </u>						
	╁	╁╴	╁	╁	╁	╁	╁	+				 			
·	<u> </u>	<u> </u>	L	1_	1_		Л.,	<u> </u>	L					L	
<u> </u>			0	TH	ER	DO	CU	ME	NTS (Inclu	ding Author, Title, Dat	e, Pertinent l	Pages, Etc.)			
Put	ŀ	198	bu e 83,	t al.	., "R l): 9	7-10	alua 30 (7	tion Abst	of response ract)	patterns of nonresponde	er mice to GL	rne polymers , j		<u>CII.,</u>	
										B Cell Responses to Dete	erminants in (Glu Lys Ala) Te	rpolymer	", <u>J.</u>	
		Im	mur	oge	net.	, 19	84,	11(3	-4): 251-25	4					
		Ba 15:		, et :	al., '	"Mu	ltipl	e Sc	lerosis: Patl	hogenesis and Treatment	", <u>Seminars i</u>	Neurol., June	994, <u>14</u> (2), 146-	
		Ba 69-		nefn	er, e	et al.	., "C	оро	lymer I as T	Therapy for Multiple Sch	erosis: The Co	ons", Neurol., 19	988, <u>38</u> (S	uppl. 2)	
		Baxevanis et al., "Genetic Control of T-Cell Proliferative Responses to Poly (Glu ⁴⁰ Ala ⁶⁰) and Poly (Glu ⁵¹ Lys ³⁴ Tyr ¹⁵): Subregion-Specific Inhibition of the Responses with Monoclonal Ia Antibodies", Immunogenetics, 1980, 11: 617-628													

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

EXAMINER

Page 5 of 16

Form PTO		-	1	Pate	ent and	Tra	nt of Comme ademark Offi	ice	Atty. Doc 60807-AA JPW/ GJG	Serial No. Not Yet Known 10/792,311				
,	IN	IFO					LOSURE CIT is if necessary		Applicants: Alexander Gad and Filing Date Group Herewith			ora Lis rt Unit		
	-						U.S. PAT	ENT DOCUMENTS				-;		
Examiner Initial	Do	ocun	nent	Nur	nber		Date	Name	Class	Subclass		Filing Date if Appropriate		
		+	-		\vdash	╀				 				
L			J	<u> </u>		—	PODEIONI	A WENT DOCUMENT						
	1						1	PATENT DOCUMENT		Τ σ ι ι	Transl	ation		
	D	ocun	nent	Nui	mber		Date Country		Class	Subclass	Yes	No		
	+	Т	$\overline{}$				 				1			
	+		++		\vdash	+	 			<u> </u>	+	 		
			<u></u>			┸		1		<u> </u>		<u> </u>		
		C	TH	ER I	DOCU	ME	NTS (Includi	ng Author, Title, Date,	Pertinent P	ages, Etc.)				
, in the second	Bo No No No Bo	243(Suppl. 1), S14-S22 Bornstein, et al., "Treatment of Multiple Sclerosis with a Synthetic Polypeptide: Preliminary Results", Ann. Neurol., 1980, 8, 117 (Abstract) Bornstein, et al., "Treatment of Multiple Sclerosis with a Synthetic Polypeptide: Preliminary Results", Trans. An Neurol. Assoc., 1980, 105, 348-350; Bornstein, et al., "Multiple Sclerosis: Trial of a Synthetic Polypeptide", Ann. Neurol., 1982, 11, 317-319; Brosnan, et al., "The Response of Normal Human Lymphocytes to Copolymer 1", J. Neuropath. Exp. Neurol.												
	19 Be	983, oms	<u>42, 3</u> tein,	356 ((Abstra	ict)		polymer 1 in Multiple Scl		-				
	Bo So H	elero ague	tein, sis"	in G 84) 1	ionsett 144-15	et al 0	., <u>Immunolog</u>	ynthetic Polypeptide (Copical and Clinical Aspects	of Multiple	Sclerosis (MTP	Press, T	he		
	19	985.	35 (Supr	ol. 1), 1	03 ((Abstract)	linical Trials of a Synthet						
	la.	dv. T	Ther.	. (US	SA), 19	87,	4, 206 (Abstra	or Patients with Exacerba						
					I., "A I 408-41		Trial of Cop	1 in Exacerbating-remitti	ng Multiple	Sclerosis", New	Eng. J. l	Med.,		
	В	orns	tein,	et a	I., "Cli	nica		with COP-1 in Multiple S						
V	Tr.	he Ir	ntern	ation	na <mark>l M</mark> u	ltipl	e Sclerosis Co	in Chronic Progressive Nonference: An Update on ther, 1989, 225-232	Iultiple Scle Multiple Scl	rosis: Prelimina l <u>erosis,</u> Roma (I	ry Repor taly), Sep	t", from stember		
EXAMINE		<u>, .,</u>	, 170	, 11			CONSIDER		/ ,					

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Page 6 of 16

Serial No. Form PTO-1449 U.S. Department of Commerce Atty. Docket No. 60807-AA-PCT-US/ Not Yet Known Patent and Trademark Office JPW/ GJG/DJK 10. 792,311 INFORMATION DISCLOSURE CITATION Applicants: Alexander Gad and Dora Lis (Use several sheets if necessary) Group Art Unit Filing Date Herewith U.S. PATENT DOCUMENTS Filing Date Document Number Name Class Subclass Examiner if Appropriate Initial FOREIGN PATENT DOCUMENTS Translation Subclass Document Number Date Class Country Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Bornstein, et al., "Clinical Trials of Cop 1 in Multiple Sclerosis" in Handbook of Multiple Sclerosis (S.D. Cook Marcel Rekker, ed., 1990) 469-480 Bornstein, et al., "A Placebo-controlled, Double-blind, Randomized Two-center, Pilot Trial of Cop 1 in Chronic Progressive Multiple Sclerosis", Neurol., 1991, 41, 533-539 Bornstein, et al., "Treatment of Multiple Sclerosis with Copolymer 1" in Treatment of Multiple Scleorsis: Trial Design, Results and Future Perspectives (Rudick R.A. & Goodkin D.E., eds., Springer Verlag, London, 1992) 173-198 Brosnan, et al., "Copolymer 1: Effect on Normal Human Lymphocytes", Ann. N.Y. Acad. Sci. (USA), 1984, <u>436,</u> 498-499 Brosnan, et al., "Immunogenic Potentials of Copolymer 1 in Normal Human Lymphocytes", Neurol., 1985, 35, 1754-1759 Burns, et al., "Human Cellular Immune Response in Vitro to Copolymer 1 and Myelin Basic Protein (MBP)", Neurol., 1985, 35 (Suppl. 1), 170 (Abstract) Burns, et al., "Human Cellular Immune Response to Copolymer 1 and Myelin Basic Protein", Neurol., 1986, <u>36,</u> 92-94 Burns, et al., "Failure of Copolymer 1 to Inhibit the Human T-cell Response to Myelin Basic Protein", Neurol., 1991, 41, 1317-1319 Carter, et al., "Newer Drug Therapies for Multiple Sclerosis", Drug Therapy, 1990, 31-32, 37-39, 42-43 Cazzato et al., "Treatment of Multiple Sclerosis. The Present and the Future. Study Group on Diagnosis and Therapy of Multiple Sclerosis", Database Medline on STN, Instituto do Clinica Neurologica, Universit`a, Trieste, Italy: Medline AN: 2000060325, Recent Progressi in Medicina, October 1999, 90(10): 538-544 Clinical Trial Protocol No. 9001, Teva Pharmaceutical Industries, Ltd., first patient enrolled October 23, Clinical Trial Protocol No. 9002, Lemmon Co. and Teva Pharmaceutical Industries, Ltd., first patient enrolled June 17, 1993 **EXAMINER** DATE CONSIDERED

EXAMINER: Initial if exption considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

Page 7 of 16

										F				
Form PTO-144	9					nt of Commended		Atty. Doc 60807-AA JPW/ GJC	-PCT-US/	Serial No. Not Yet Known 10/792,311				
	INF	ORM	ITAI	ON DE	SCI	OSURE CIT	FATION	Applicant	s: Alexander Ga		7			
						s if necessary			s. Alexander Ga	1				
				-				Filing Date Herewith		Group A	544 544			
						U.S. PAT	ENT DOCUMENTS							
Examiner Initial	Doc	umen	t Nu	mber		Date	Name	Class	Subclass		Filing Date if Appropriate			
			+		┞	 			 	-				
			ŀ	<u> </u>	<u>!</u>	FOREIGNI	A GUENTE DO CHIA FENT		<u> </u>	J				
	E -					T	PATENT DOCUMENT			Transl	ation			
	Doc	umen	t Nu	mber		Date	Country	Class	Subclass	Yes	No			
	h		Ţ.	П	Т	 				1				
	-		╁╌	╁╌┟╌	╁			 		 				
ļl	<u> </u>													
	T	OTH	ER	DOCU	ME	NTS (Includi	ng Author, Title, Date,	Pertinent I	Pages, Etc.)					
Put		•			estemic Autoimmunity, 4									
1	The COP-1 Multicenter Clinical and Research Group Study, "COP-1 Multicenter Trial in Relaps													
	Remitting Multiple Sclerosis: 3 Year Follow Up", <u>Abstracts of Symposia and Free Communication</u> , Barcelona (Spain), June 25-29, 1994, <u>241</u> (Suppl. 1), 6													
	Cot 139	ton, "C	Optio	ns for N	lulti	iple Sclerosis	Therapy", J.A.M.A. Med	tical News &	& Perspectives,	1994, <u>27</u> 2	2(18),			
	Dee (TC	b et al	l., "C in ral	omparis bbits", <u>J</u>	ion . Im	of Freund's a munol. Metho	and Ribi adjuvants for incods, 1992, 152(1): 105-1	lucing antib 13 (Abstrac	odies to the synt t)	hetic anti	gen			
	De	Kruyf	f et a	l., "Ana	lysi	of T Cell Re	sponses to Poly-L (GluL	ys) at the Cl	onal Level. I. P	resence o	f			
	Res	ponsiv	e Cl	ones in	Nor	responder Mi	ice", Eur. J. Immunol., 19	987, 17 (8):	1115-1120 (Ab	stract)				
							ting", <u>Curr. Opinions Im</u> ple Sclerosis", <u>Instituto c</u>			Sistema	Nervos			
	Uni	em, iversita	a di T	orino, 4	167-	475;	pie sciciosis, <u>mismuto v</u>	ii Cimica de	one programme del	Coisterna	1.0(1.03			
	Fal	o et al.	., "Aı	nalysis c	of ar	tigen present	ation by metabolically in	active acces	sory cells and th	icir isolat	ed			
	men	mbran	es", <u>F</u>	Croft '	tl. /	Acad. Sci. US	A, 1985, 82(19): 6647-6 ase", New Eng. J. Med.,	1991, 324	667-674		·			
							ple Sclerosis", J. Clin. P			1993, 18.	77-84			
							splaces MBP, PLP and M							
	Ant	tigens titute (from of Sci	the MI ence, 19	IC (Class II Bindir	ng Site", <u>Department of (</u>	Chemical Im	munology, The	Weizman	ın ·			
	Frie His	dkis-H tocom	areli, patib	et al., ' oility Co	Dir mpl	ect Binding o	f Myelin Basic Protein a on Living Antigen-Prese 4872-4876	nd Synthetic enting Cells	Copolymer 1 to - Specificity and	o Class II d Promisc	Major uity",			
EXAMINER	٠١	51.		DA	TE	CONSIDER	ED /	14/04						
AFY A MINIED A	/V .		n con	cidered ·	whet	er or not citatio	n is in conformance with MP	EP 609: Draw	line through citatio	n if not in				
conformance and	not co	nsidere	d. Incl	lude copy	of t	his form with ne	xt communication to applicar	ıL						

Page 8 of 16 U.S. Department of Commerce Atty. Docket No. Serial No. Form PTO-1449 Not Yet Known 60807-AA-PCT-US/ Patent and Trademark Office JPW/ GJG/DJK 10/792311 INFORMATION DISCLOSURE CITATION Applicants: Alexander Gad and Dora Lis (Use several sheets if necessary) Filing Date Herewith U.S. PATENT DOCUMENTS Filing Date Class Subclass Document Number Name Examiner if Appropriate Initial FOREIGN PATENT DOCUMENTS Translation Class Subclass Document Number **Date** Country Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Fridkis-Hareli, et al., "Specific and Promiscuous Binding of Synthetic Copolymer 1 to Class II Major Histocompatibility Complex Molecules on Living Antigen Presenting Cells", Israeli Biochem. Soc., 1994. Fridkis-Hareli, et al., "Synthetic Copolymer 1 Inhibits the Binding of MBP, PLP and MOG Peptides to Class II Major Histocompatibility Complex Molecules on Antigen Presenting Cells" in Neurochem Mtg., August Fridkis-Hareli, et al., "Synthetic Copolymer 1 Inhibits the Binding of MBP, PLP and MOG Peptides to Class I Major Histocompatibility Complex Molecules on Antigen-Presenting Cells", J. Neurochem., 1994, 63 (Suppl. I) Fridkis-Hareli, et al., "Synthetic Copolymer 1 and Myelin Basic Protein do not Require Processing Prior to Binding to Class II Major Histocompatibility Complex Molecules on Living Antigen Presenting Cells", Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot, Israel, 1994 Fridkis-Hareli, et al., "Synthetic Copolymer 1 and Myelin Basic Protein Do Not Undergo Processing Prior to the Binding to Class II Major Histocompatibility Complex Molecules on Antigen Presenting Cells", Israeli Immunol. Soc., May 3-4, 1994 (Abstract) Fridkis-Hareli, et al., "Synthetic Copolymer 1 and Myelin Basic Protein Do Not Require Processing Prior to Binding to Class II Major Histocompatibility Complex Molecules on Living Antigen-Presenting Cells", Cell. Immunol., 1995, 163, 229-236 Fridkis-Hareli, et al., "Promiscuous Binding of Synthetic Copolymer 1 to Purified HLA-DR Molecules", J. <u>Immunol., 1998, 160, 4386-4397</u> Fridkis-Hareli, et al., "Synthetic Amino Acid Copolymers that Bind to HLA-DR Proteins and Inhibit Type II Collagen-Reactive T Cell Clones", Proc. Natl. Acad. Sci., 1998, 95, 12528-12531 Fridkis-Hareli et al., "Binding of random copolymers of three amino acids to class II MHC molecules", Intl.

EXAMINER

DATE CONSIDERED

Immunol., 1999, 11(5): 635-641

Israel J. Med. Sci., 1993 (Abstract)

*EXAMINED: Initial if chation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Macrophage Procoagulant Activity Assay", Int. Immunol., 1990, 2(8), 713-718

Fridkis-Hareli et al., "Synthetic Peptides that Inhibit Binding of the Collagen Type II 261-273 Epitope to Rheumatoid Arthritis-Associated HLA-DR1 and DR4 Molecules and Collagen-Specific T-cell Responses", Database HCAPLUS on STN, Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark, HCAPLUS AN: 2000:455053, Human Immunology, 2000, 61(7): 640-650 (Abstract)

Grgacic, et al., "Cell-mediated Immune Response to Copolymer 1 in Multiple Sclerosis Measured by the

Gurevich, "Study of the MHC-competition Between BP and Cop 1 Using Human Cytotoxic T-cell Clones",

Page 9 of 16

Form PT	O-144]	Patent	and T	(ra	t of Commer demark Offi	ce	JPW/ GJG	-PCT-US/ s/DJK	Not Yet / 6/79	Serial No. Not Yet Known 16/792,311		
	٠.	INFO					OSURE CIT if necessary		Applicant	s: Alexander Ga	d and Do	ra Lis		
			(US	e seve	rai sii	cers	in necessary		Filing Date Herewith	•		Group Art Unit 1644		
							U.S. PAT	TENT DOCUMENTS						
Examine Initial	r	Docun	nent	Numt	er ·		Date	Name	Class	Subclass		Filing Date if Appropriate		
		 	1	\sqcup	1-1	_				ļ				
			1	ш			FOREICNI	A TENT DOCUMEN	Te		-l			
	T	-						PATENT DOCUMEN	Class	Subclass	Transl	ation		
-		Docun	nent	Numi	oer		Date	Country	Class	Subclass	Yes	No		
-	1	$\dagger \top$	Т	П					,					
	+	 	†			-			.					
		بلل					TTC (I1 1	I Author Title Det	a Dantinant I	Page Eta)	. .	L		
		Uarrie	ODA	ek De	JCUM	nti	en-Specific	ng Author, Title, Date Therapy for Autoimme	ne Disease".	Current Opin, Ir	nmunol	2000.		
-01		12(6):			ici, 7		,	Thorapy for reaconsmiss	,.					
1241	-	Henry	Cel	ia M	"Spec	ial I	Delivery" Cl	hem and Eng. News. S	ept. 18, 2000.	49-54	-			
	1	Henry, Celia M., "Special Delivery", Chem. and Eng. News, Sept. 18, 2000, 49-54 Herzenberg et al., "Lack of immune response gene control for induction of epitope-specific suppression by TG												
	 													
							5: 329-331 (<i>i</i>				•			
 	+	lacobs	et	al. "A	dvance	es in	Specific Th	erapy for Multiple Scle	erosis". Neuro	<u>1., 1994, 7, 250</u> -	254			
	1		,	,	•									
 	+	Johnso	on. "	Clinica	al Stud	ies	in Copolyme	er 1 Therapy for Exacer	bating-remitti	ng Multiple Scl	erosis", i	n		
		Congr	ess f	or Adv	vances	in I	the Understa	nding and Treatment of	f Multiple Sclerosis, Boston (USA), Oct. 28-29					
<u> </u>	-	1992	"	Evnori	manta	ı Tı	arany of Pal	apsing-Remitting Mult	inle Sclerosis	with Conglyme	r-1". Ann			
		Neuro	1., 19	994, 30	6(Supp	ıl.),	115-117							
		Johns	on, N	/lanage	ement e	of F	Relapsing/Re	mitting Multiple Sclero	sis with Copo	lymer l (Copax	one)", <u>Cl</u>	emical		
 	+	Abstra	icts,	1996,	125, 2	919 Ivei	93b s of antibodi	es against the terpolym	er L-glutamic	acid 60-L-alani	ne30-L-			
		tyrosi	ne 10	(GAT). IV.	Ind	uction of CG	AT idiotype following	immunization	with various sy	nthetic p	olymers		
	\bot	contai	ning	glutar	nic aci	d a	nd tyrosine",	Eur. J. Immunol., 1979	9, 9(<u>7): 553-5</u> 6	60 (Abstract)				
.		Kay, 6	et al.,	, The	Mecha	anis	m of Action	of FK 506", Transplan	tadon Proceed	ings, 1770, <u>44</u> (1, 3uppi.	1), 20-		
	+-	Keith,	et a	I., "Th	e Effe	ct o	f COP 1, a S	ynthetic Polypeptide, o	n Chronic Rel	apsing Experim	ental Alle	ergic		
	-	Encep	halo	myelit	is in G	uin	ea Pigs" J. N	leurol. Sci., 1979, 42, 2	Cronsplantatio	n: Evnerimental	Laborat	ory and		
		Kelen	nan, al C	et al., ' ontrib	Graft- utions	-ver of t	sus-most Dis he Last Few	ease in Bone Marrow Years", Int. Arch. Aller	rey Immunol.,	1993 <u>, 102</u> , 309	-320	, and		
17		Kepsi	ıtlu e	et al "	Evalua	atio	n of Chitosar	Used as an Excipient	in Tablet Forn	nulations", Data	ibase HC	APLUS		
$ \forall$		on ST	N, E	Departi	nent of	f Ph	narmaceutica	Technology, Gulhane , Acta. Pol. Pharm. 199	Military Med	ical Academy, <i>F</i> 235 (Abstract)	Ankara, U	6018,		
EW 43 CT		Li urke	у, п	CAPL					, , , <u>, , , , , , , , , , , , , , , , </u>	(, 103(1451)		• • • •		
EXAMI	NER	1	sh		DA	ıŁ	E CONSIDERED							
		nitial if c	dio	consid	lered w	heth	er or not citatio	on is in conformance with M	1PEP 609: Draw	line through citatio	on if not in			
conforman	ice and	not consi	dered	. Includ	le copy	of th	is form with ne	ext communication to applic	cant.					

Page 10 of 16 Atty. Docket No. Serial No. Form PTO-1449 U.S. Department of Commerce 60807-AA-PCT-US/ Not Yet Known Patent and Trademark Office 792311 JPW/ GJG/DJK INFORMATION DISCLOSURE CITATION Applicants: Alexander Gad and Dora Lis (Use several sheets if necessary) Group Art Unit Filing Date Herewith **U.S. PATENT DOCUMENTS** Class Subclass Filing Date Date Examiner Document Number Name if Appropriate Initial FOREIGN PATENT DOCUMENTS Translation Class Subclass Country Document Number Date No Yes OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Kott, et al., "COP-1 Increases Suppressor Cells Number in Multiple Sclerosis", Israel Neurological Assoc., Putt December 19-20, 1994, Herzliya (Israel), 17 Kropshofer et al., "Self-Peptides from Four HLA-DR Alleles Share Hydrophobic Anchor Residues Near the NH₂-Terminal Including Proline as a Stop Signal for Trimming", <u>J. Immunol.</u>, 1993, 151: 4732-4742 Lai et al., "Complementation of Class II A alleles in the immune response to (GluLysTyr) polymers", Exp. Clin. Immunogenet., 1986, 3(1): 38-48 (Abstract) Lai et al., "Monoclonal T cell responses to two epitopes on a single immunogen controlled by two distinct genes", J. Immunol., 1986, 136(10): 3799-3804 (Abstract) Lando, et al., "Effect of Cyclophosphamide on Suppressor Cell Activity in Mice Unresponsive to EAE", <u>I.</u> Immunol., 1979, 123, 2156-2160 (Abstract) Lando, et al., "Experimental Allergic Encephalomyelitis in Mice - Suppression and Prevention with COP-1", Israel J. Med. Sci., 1979, 15, 868-869 (Abstract) Lee, et al., "Peptide and Protein Drug Delivery" in Advances in Parenteral Sciences (Vincent H.L. Lee, ed., Marcel Dekker, Inc., 1990) 691-695 Li et al., "Glatiramer acetate blocks the activation of THP-1 cells by interferon-y", Eur. J. Pharmacol., 1998, 342: 303-310 Lisak, et al., "Effect of Treatment with Copolymer 1 (Cop-1) on the in Vivo and in Vitro Manifestations of Experimental Allergic Encephalomyelitis (EAE)", J. Neurol. Sci., 1983, 62, 281-293 Matsunaga et al., "Complementation of Class II A alleles in the immune response to (Glu-Lys-Tyr) polymers", Yokohama Med. Bull., 1988, 39(1-2): 9-19 (Abstract) Maurer et al., "Interpretations of immune responses of mice to poly(Glu60Lys40), its modified derivatives, and the terpolymers poly (Glu55Lys37Leu8) and poly (Glu56Lys37Ser7)", Clin. Immunol. Immunopathol., 1980, 15(3): 344-356 (Abstract)

McDermott, et al., "Antigen-induced Suppression of Experimental Allergic Neuritis in the Guinea Pig", <u>1.</u>

EXAMINER ,

DATE CONSIDERED

EXAMINER: Initial of citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in

conformance and not donsidered. Include copy of this form with next communication to applicant.

Neurol. Sci., 1980, 46, 137-143

Form PTO-	1449						nt of Commer demark Offi		Atty. Doc 60807-AA JPW/ GJG	-PCT-US/	Serial No. Not Yet Known				
	IN						OSURE CIT			: Alexander Ga	d and Do	ra Lis			
					1 41 51				Filing Date Group Art Unit Herewith LAG						
							U.S. PAT	ENT DOCUMENTS							
Examiner Initial	Do	cume	nt	Numb	er		Date	Name	Class	Subclass	Filing Date if Appropriate				
		╁┼	\dashv	- 		₩	 			}	├──				
						т—	EODEICNI	L CHARLES DO CHILADAITE	. 	!	L				
			_					PATENT DOCUMENTS		Υ	Translation				
ĺ	Do	cume	nt i	Numb)er		Date	Country	Class	Subclass					
-	-	ТТ	_		$\overline{}$					 	Yes	No			
		\vdash	-	$\vdash \vdash$	┿	╀			 	ļ	<u> </u>				
]			丄			<u> </u>	<u> </u>					
		ОТ	HE	er do	CUP	ME	NTS (Includi	ng Author, Title, Date, I	Pertinent P	ages, Etc.)		İ			
Puk		iner,	"C	OP-1 I	Multi	cent		ial in Exacerbating-remit			Year Fo	illow-			
1	Meiner, et al., "The Israeli COP-1 Multicenter Clinical Trial in Exacerbating-rem										ple Scler	osis -			
	Two-year Follow-up", in 9th Congress of the European Committee for Treatment and Research in M											tiple			
Sclerosis, Florence (Italy), October-November, 1993, 48 (Abstract) Mengle-Gaw, "The Major Histocompatibility Complex (MHC)", in Encycl. Molecular Bio.										, i b D: //	- I D				
				w, "Th l, 1994				bility Complex (MHC)", i	n <u>Encycl. N</u>	<u>lolecular Bio</u> . (C	Oxford Blackwell				
				"Inhi 86 (Al			Myelin Basic	Protein-specific Human	T-cell Lines by COP-1", <u>Israel J. Med. Sci.</u> ,						
	1 N	1onoc	cyte		ropha	ige (Cell Line" in]		expression and Cytokine Synthesis in the THP- n Multiple Sclerosis, San Diego (USA),						
	Mi	lo, et	al.,	"Add	litive	Effe	cts of COP-1	and IFN-Beta on Immuno	une Responses to Myelin Basic Protein",						
							e), A212				4 -1' D				
								mer-1 and Interferon-β or Sackler School of Medic							
				<u>1edici</u>				. Sackier School of Medic	711C, 1C1-71	TIV OHIVEISH O	14101 7 101	<u>.u</u>			
	Mi	lo, et	al.,	"Cop	olym	er-l	and Interfero	n-β Additively Suppress t			elin Bas	ic			
								on", J. Neuroimmunol., 1			7. "				
							cts of Copoly [., 1995, <u>61</u> , 1	mer-1 and Interferon β-11	on the Im	mune Response	io Myelli	n Basic			
	Му	ers, e	t al		e Pec			of Therapeutic Trials for	Multiple Sc	lerosis", Neurol	ogic Clir	iics,			
	Nig		gale	, et al.		ces	s to Investigat	ional Drugs for Treatmen	t Purposes"	, Am. Family Ph	ysician,	1994,			
					"Pow	der	s" in The Scie	nce and Practice of Pharm	nacy, Remi	ngton, 1995, <u>2</u> , 1	598-161	4			
EXAMINER	٦ .	 V			DA	TE	CONSIDERE	D 12/14/04							
•EXAMINER	: Initial i	citati	ion o	conside	red, w	heth	er or not citation	is in conformance with MPER	609: Draw li	ne through citation	if not in				

Page 12 of 16

Form PTO-14]	Paten	t and	Tra	t of Commer demark Offi	ce	Atty. Docl 60807-AA JPW/ GJG	-PCT-US/	Serial No. Not Yet Known Lo/792,31				
	INFO					OSURE CIT		Applicants	: Alexander Ga	ıd and Do	ra Lis			
•	•	(US	se sev	erai si	1665	s if necessary		Filing Date Herewith		Group A	t Unit 44			
						U.S. PAT	ENT DOCUMENTS							
Examiner Initial	Docu	ment	Num	ber	T	Date	Name	Class	Subclass	Filing I				
			++	+	╀		<u> </u>							
<u> </u>			<u>lL</u>		ــــــــــــــــــــــــــــــــــــــ	FOREICNE	ATENT DOCUMEN	TS						
	1.						PATENT DOCUMEN			Transl	ation			
	Docu	ment	Num	ber		Date	Country	Class	Subclass	Yes	No			
	+	1	П	\neg	Т									
	++	┥	1	_	╁					+				
				L_		<u> </u>			L	<u> </u>	\vdash			
		HTC	ER D	OCU	ME	NTS (Includi	ng Author, Title, Date	e, Pertinent P	ages, Etc.)					
1.	Pende	er, et	al., In	ternal	Med	d. Journal, 20	02, 32: 554-563							
PIK	1							•						
. 1	Porte	r, "Co	ating	of Ph	arm	aceutical Dos	age Forms," in The Sci	ence and Prac	tice of Pharmac	y, Remin	gton,			
	1995,													
	Prat e	t al	"Lvn	nhocy	te N	digration and	Multiple Sclerosis: Re	lation with Di	sease Course ar	nd Therap	y." <u>Ann.</u>			
Neurol., 1999, 46: 253-256														
	Duri		"Ma	dulatio	n of	the Immune	Response in Multiple S	Clerosis". J. II	nmunol., 1997.	158, 247	1-2476			
	Гшт	i il.,	IVIO	Juiatio	ni Oi	of the Immune Response in Multiple Sclerosis", J. Immunol., 1997, 158, 2471-2476								
	Rack	e et a	ıl. "C	`onoly	mer-	r-1-induced Inhibition of Antigen-specific T Cell Activation: Interference with								
	Antio	en Pi	resent	ation"	. J. 1	Neuroimmunol., 1992, 37, 75-84 aceutical Necessities" in The Science and Practice of Pharmacy, Remington 1995, 2,								
				, "Pha	rmac	ceutical Neces	ssities" in The Science	and Practice o	f Pharmacy, Re	mington	1995, <u>2,</u>			
ļ	1380	-1416	5	17	The	for Multi	iple Sclerosis", Clin. N	europharmaco	logy 1987 100	5), 389-3	96			
	Rolai	k, "C	opory	mer-1	1 nei	apy for Multi	Immunogenic Peptides	and MHC Pro	teins" Ann Re	ev Immu	nol			
			et ai. 27-56		racu	ons between	mmunogeme i epudes	and wife in	, <u>, , , , , , , , , , , , , , , , , , </u>					
	Salve	tti. e	t al., '	'Myeli	n Ba	asic Protein T	Cell Epitopes in Patier	nts with Multip	ole Sclerosis", I	Departme	nt of			
	Neur	ologi	cal So	ciences	s. Ut	niversity of Re	ome, La Sapienza 1991	, 72 (Abstract)					
	Schle	gel,	et al.,	"Preve	entic	on of Graft-Ve	ersus-Host Disease by	Peptides Bindi	ng to Class II N	viajor				
	Schle	comp	patibi	"Inhih	vitio	n of Alloreco	", Blood, 1994, 84(8), gnition and Prevention	of Graft-vs-ho	st Disease (GV	HD) by C	GLAT, a			
	Syntl	hetic	Polyn	ner wit	th Pi	romiscuous B	inding to Murine and H	Iuman MHC C	llass II Molecul	les", ın <u>A</u> ı	m. Soc.			
	Hem	atolo	ev. 37	^{дь} Апл	ual	Meeting, Seat	tile, WA (USA), Decer	nber 1-5, 1993	, 224a (Abstrac	ct)				
	(Glu	57Ly:	et al., s38Ty Abstr	/r5): E	vide	mplementation ence for effect	n in the T lymphocyte parts of polymer handling	proliferative re and gene dosa	sponse to poly ge", <u>J. Immuno</u>	<u>1</u> ., 1979, 1	123(1):			
EXAMINER	7.				TE	TE CONSIDERED 12/14/04								
*EXAMINER:	Initial if	citatio	n cons	idered, v	whed	her or not citatio	on is in conformance with M	IPEP 609: Draw	line through citation	on if not in				
conformance and	1 not don:	siderec	i. Inclu	ide copy	y of t	his form with ne	ext communication to applic	ant.		_				

Page 13 of 16

Atty. Docket No. Serial No. Form PTO-1449 U.S. Department of Commerce 60807-AA-PCT-US/ Not Yet Known Patent and Trademark Office 792,311 JPW/ GJG/DJK INFORMATION DISCLOSURE CITATION Applicants: Alexander Gad and Dora Lis (Use several sheets if necessary) Group Art Unit Filing Date Herewith U.S. PATENT DOCUMENTS Class Subclass Filing Date Document Number Date Name Examiner if Appropriate Initial FOREIGN PATENT DOCUMENTS Translation Class Subclass Document Number Date Country Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Sela, et al., "Experimental Allergic Encephalomyelitis" in Menarini Series on Immunopathology, vol. 1, First Symposium of Organ Specific Autoimmunity", Cremona, Italy, June, 1977, (Miescher P.A. ed., Schwabe Co., Put Basel, 1978), 9-21 Sela, et al., "Suppressive Activity of COP-1 in EAE and its Relevance to Multiple Sclerosis", Bull. Inst. Pasteur, 1990, 88, 303-314 Sela, "Polymeric Drugs as Immunomodulatory Vaccines Against Multiple Sclerosis", Makromol. Chem. Macromol. Symp., 1993, 70/71, 147-155 Starzl, Transplantation Proceedings, 1990, 22 (1, Suppl. 1), 5 Stark, "Expanded Clinical Trials of Treatments for Multiple Sclerosis (MS): Copolymer 1 (COP-1) Treatment Investigational New Drug (IND) Program", Ann. Neurol., 1994, 36, 114-115 Sykes, "Immunobiology of Transplantation", Faseb J., 1996, 10, 721-730 Tarcic et al., "Copolymer I (Copaxone) from an Idea to a Drug for Treatment of Multiple Sclerosis" Database HCAPLUS on STN, Israel: AN 1997:333270. Kim, Handasa Kim, 1997, 281(14), 16-18 (Abstract) Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Polypeptide", <u>Eur. J. Immunol., 1971, 1, 242-248</u> Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Polypeptide", Israel J. Med. Sci., 1971, 7, 630-631 (Abstract) Teitelbaum, et al., "Protection Against Experimental Allergic Encephalomyelitis", Nature, 1972, 240, 564-Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis with Basic Polymers", Eur. J. <u>lmmunol., 1973, 3, 273-279</u> Teitelbaum, et al., "Dose-response Studies on Experimental Allergic Encephalomyelitis Suppression by COP-1", Israel J. Med. Sci., 1974, 10(9), 1172-1173 DATE CONSIDERED EXAMINER

*EXAMINER: Initial in citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Page 14 of 16 Serial No. Atty. Docket No. U.S. Department of Commerce Form PTO-1449 Not Yet Known 60807-AA-PCT-US/ Patent and Trademark Office JPW/ GJG/DJK 18/792311 INFORMATION DISCLOSURE CITATION Applicants: Alexander Gad and Dora Lis (Use several sheets if necessary) Group Art Unit Filing Date Herewith **U.S. PATENT DOCUMENTS** Filing Date Class Subclass Date Name Examiner Document Number if Appropriate Initial FOREIGN PATENT DOCUMENTS Translation Subclass Document Number Class Country Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis in Rhesus Monkeys by a Synthetic Basic Copolymer", Clin. Immunol. Immunopath., 1974, 3, 256-262 Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis in Baboons by Cop 1", Israel J. Med. Sci., 1977, 13, 1038 (Abstract) Teitelbaum, et al., "Blocking of Sensitization to Encephalitogenic Basic Protein in Vitro by Synthetic Basic Copolymer (COP 1)" in Cell Biology and Immunology of Leukocyte Function (Academic Press, New York 1979) 681-685 Teitelbaum, "Suppression of Experimental Allergic Encephalomyelitis with a Synthetic Copolymer -Relevance to Multiple Sclerosis", in Humoral Immunity in Neurological Diseases (Karcher D., Lowenthal A. & Strosberg A.D., eds., Plenum Publishing Corp., 1979) 609-613 Teitelbaum, et al., "Monoclonal Antibodies to Myelin Basic Protein Cross React with Synthetic EAEsuppressive Copolymer, COP 1" in Proc. 7th Eur. Immunol. Mtg., Jerusalem, September 8-13, 1985 (Abstract) Teitelbaum, et al., "Specific Inhibition of the T-cell Response to Myelin Basic Protein by the Synthetic Copolymer Cop 1", Proc. Natl. Acad. Sci. USA, 1988, 85, 9724-9728 Teitelbaum, et al., "Clinical Trial of Copolymer 1 in Multiple Sclerosis" J. Israel Med. Assoc., 1989, CXVI(9), 453-456 Teitelbaum, et al., "Cross-reactions and Specificities of Monoclonal Antibodies Against Myelin Basic Protein and Against the Synthetic Copolymer 1", Proc. Natl. Acad. Sci. (USA), 1991, 88, 9528-9532 Teitelbaum, et al., "Synthetic Copolymer 1 Inhibits Human T-cell Lines Specific for Myelin Basic Protein", Proc. Natl. Acad. Sci. (USA), 1992, 89, 137-141 Teitelbaum, et al., "Immunological Parameters in a Multicenter Clinical Trial of COP1 in Multiple Sclerosis (MS): A 2-year Follow-up", Neurol., 1994, 44(Suppl. 2), A358 Teitelbaum, et al., "Copolymer 1 Inhibits Chronic Relapsing Experimental Allergic Encephalomyelitis Induced by Proteolipid Protein (PLP) Peptides in Mice and Interferes with PLP-specific T Cell Responses", L

EXAMINER DATE CONSIDERED

Neuroimmunol., 1996, 64, 209-217

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Teitelbaum, et al., "Copolymer 1 from the Laboratory to FDA", Israel J. Med. Sci., 1997, 33, 280-284

Page 15 of 16

Form PTO-	1449					nt of Comme ademark Offi		Atty. Doc 60807-AA JPW/ GJC	-PCT-US/	Not Yet	Serial No. Not Yet Known			
l .	INF					OSURE CIT		Applicant	s: Alexander Ga	d and Do	ra Lis			
		(U:	se se	verai:	sneei	s if necessary	,, 	Filing Date Herewith		Group A				
						U.S. PAT	TENT DOCUMENTS				1			
Examiner Initial	Doc	ıment	Nui	mber		Date	Name ·	Class	Subclass		Filing Date if Appropriate			
			<u> </u>		\downarrow					 				
			l	Щ.		L	<u> </u>			<u> </u>				
	- r					FOREIGN I	PATENT DOCUMENT	<u>s</u>		Transl	ation			
	Doc	ıment	Nui	mber		Date	Country	Class	Subclass					
			_	т т	1	<u> </u>		+	-	Yes	No			
<u> </u>	-	_	_	$\sqcup \bot$	4									
										<u> </u>	<u> </u>			
	-	отн	ER I	DOCU	MЕ	NTS (Includi	ng Author, Title, Date,	Pertinent I	Pages, Etc.)					
Pulk	Thomas 141				, Immunol, Tod	ay, 1985,	<u>6</u> (4),							
		Tisch et al., "Antigen-specific immunotherapy: Is it a Real Possibility to Combat T-Cell-Mediated autoimmunity16" Proc. Natl. Acad. Sci. U.S.A., 1994, 91, 437-438												
	I-A ((Abs Van	does n tract) den B	ot in	rde, e	e the	restriction of	ion of the T cell repertoin f hapten-specific T cells' Long-Term Survival of l	, <u>Eur. J. Im</u>	<u>munol</u> ., 1985, 1	5(12): 12				
							of Cytology, 1996, 178:							
\vdash	Cop	olyme	r", <u>Is</u>	rael J.	Med	<u>l. Sci., 1972, 8</u>	8, 656-657	ntal Allergic Encephalomyelitis by Synthetic Sclerosis (letter)" Neur. Neurochir. Pol., 1990,						
	24, 1	13	•	•										
,				et al., ' 1992,			nd Treatment of Multiple	Sclerosis",	Current Opinioi	in Neuro	ol. and			
	Web Synt	b, et a hetic l	d., "l Basic	ln Viv	o and pepti	l in Vitro Imm des Capable o	nunological Cross-reaction of Suppressing Experiment							
	Web	b, et a	d., "	Suppre	ssio	of Experime	ntal Allergic Encephalor 75, <u>11</u> , 1388 (Abstract)	nyelitis in R	hesus Monkeys	by a Synt	hetic			
	Wet	b, et a	il., "	Molec	ular l	Requirements iem., 1976, <u>13</u>	Involved in Suppression	of EAE by	Synthetic Basic	Copolym	ers of			
4	Wet	ster's 1, page	ΠN	ew Ri	versi	de University	Dictionary, definition of	"preventing	", The Riversid	Publishi	ng Co.,			
EXAMINE	•		··		DATE CONSIDERED 72/14/04									
•EXAMINER							n is in conformance with MPI xt communication to applican		line through citatio	n if not in				

Page 16 of 16 Serial No. Atty. Docket No. Form PTO-1449 U.S. Department of Commerce Not Yet Known 60807-AA-PCT-US/ Patent and Trademark Office JPW/ GJG/DJK <u> 10/792,311</u> INFORMATION DISCLOSURE CITATION Applicants: Alexander Gad and Dora Lis (Use several sheets if necessary) Group Art Unit Filing Date Herewith 1644 U.S. PATENT DOCUMENTS Filing Date Class Subclass Document Number Date Name Examiner if Appropriate Initial FOREIGN PATENT DOCUMENTS Translation Class Subclass Date Country Document Number Yes OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Winer, "COP 1 Therapy for Multiple Sclerosis", New Eng. J. Med., 1987, 317(7), 442-444 Zisman et al., "Dichotomy between the T and the B cellepitopes of the synthetic polypeptide (T,G)-A--L", Eur. J. Immunol., 1994, 24(10): 2497-2505 (Abstract) Zisman et al., "Direct binding of a synthetic multichain polypeptide to Class II Major Histocompatibility Complex molecules on Antigen-Presenting Cells and stimulation of a specific T-cell line require processing of the polypeptide", Proc. Natl. Acad. Sci. USA, 1991, 88(21): 9732-9742 (Abstract)

EXAMINER

DATE CONSIDERED

*EXAMINED: Initial if quition considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

: Herewith

Applicants

: Alexander Gad and Dora Lis

Serial No. : 1

: Not Yet Known (Continuation of U.S. Serial

No. 09/816,989, filed March 32, 2001)

Filed

Page 28

August 21, 2002, October 18, 2002, and June 25, 2003. The below listed references 162, 202 and 209 were cited by the Examiner on PTO Form 892 issued on March 25, 2003 in connection with U.S. Serial No. 09/816,989.

Accordingly, under 37 C.F.R. §1.98(d) copies of references 1-23, 25-27, and 30-209 are not required to be provided to the United States Patent and Trademark Office because they were previously submitted to or cited by the United States Patent and Trademark Office in an application relied upon for an earlier filing date under 35 U.S.C. §120.

Copies of the below listed references 24, 28 and 29 are enclosed herewith as Exhibits 1.3.

- 1. U.S. Patent No. 3,819,550, issued November 19, 1974 (Teitelbaum, et al.)
- 2. U.S. Patent No. 3/991,210, issued November 9, 1976 (Shea);
- 3. U.S. Patent No. 4,339,431, issued July 13, 1982 (Gaffar);
- 4. U.S. Patent No. 5,204,099, issued April 20, 1993 (Barbier, et al.);
- 5. U.S. Patent No. 5,554,372, issued September 10, 1996 (Hunter et al.);

189 N. 8

: Alexander Gad and Dora Lis

: Herewith

Serial No.

: Not Yet Known (Continuation of U.S. Serial

No. 09/816,989, filed March 32, 2001)

Filed

Page 29

- 6. U.S. Patent No. 5,583,031, issued December 10, 1996 (Stern);
- 7. U.S. Patent No. 5,591,629, issued January 7, 1997 (Rodriguez et al);
- 8. U.S. Patent No. 5,623,052, issued April 22, 1997 (McLean et al.);
- 9. U.S. Patent No. 5,627,206, issued May 6, 1997 (Hupe, et al.);
- 10. U.S. Patent No. 5,668,117, issued September 16, 1997
 (Shapiro et al.);
- 11. U.S. Patent Nor 5 719,296, issued February 17, 1998 (Acton, III, et al.);
- 12. U.S. Patent No. 5,734,023, issued March 31, 1998 (Bishwajit et al.);
- 13. U.S. Patent No. 5,800,808, issued September 1, 1998 (Konfing, et al.);
- 14. U.S. Patent No. 5,858,964, issued January 12, 1999 (Abaroni, et al.);
- 15. U.S. Patent No. 5,886,156, issued March 23, 1999 (McLean et al.);
 - (6. U.S. Patent No. 5,958,972, issued September 28, 1999 (Hupe, et al.);

Pg & Ja

Applicants : Alexander Gad and Dora Lis

: Herewith

Serial No.

: Not Yet Known (Continuation of U.S. Serial

No. 09/816,989, filed March 32, 2001)

Filed

Page 30

- 17. U.S. Patent No. 5,981,589, issued November 9, 1999 (Konfino, et al.);
- 2000 issued April 1/1, 18. U.S. Patent No. 6,048,898, (Konfino, et al.);
- U.S. Patent No. 6,054,430, issued April 25, 19. (Konfino, et al.);
- 2001 issued April 10, 6,214,791/ U.S. Patent No. 20. (Arnon, et al.);
- Assued January 29, 2002 U.S. Patent No. 6,342 476, 21. (Konfino, et al.);
- 6362,161, issued March 26, 2002, U.S. Patent No. 22. (Konfino et al.);
- U.S. Patent No. 6,5/4,938, issued February 4, 2003 (Gad 23. et al.);
- U.S. Patent Ng. 6,620,847, issued September 16, 2003 24. (Konfino, et al.) (Exhibit 1)
- No. US-2001-0055568-A1, Patent Publication published December 27, 2001 (Gilbert et al.);
- Publication No. US-2002-0037848-A1, Patent 26. U.S. published March 28, 2002 (Eisenbach-Schwartz et al.);

: Alexander Gad and Dora Lis

: Herewith

Serial No.

: Not Yet Known (Continuation of U.S. Serial

No. 09/816,989, filed March 32, 2001)

Filed

Page 31

27. U.S. Patent Publication No. US-2002-0107388-A1, published August 8, 2002 (Vandenbark);

- 28. U.S. Patent Publication No. 2002-0115103-A1 (U.S. Serial No. 09/816,989, filed March 23, 2001) published August 22, 2002 (Gad et al.)(Exhibit 2). Applicants point out that 2002-0115103-A1 is a counterpart of PCT/US99/22402 and U.S. Patent No. 6,514,938 (Items 49 and 23 respectively) as well as the parent of the subject application;
- 29. Pending claims as of March 1, 2004 of U.S. Serial No. 09/816,989 (Gad et al.)(Item 28)., U.S. Patent Publication No. 20020115103 A1, for the Examiner's convenience, (Exhibit 3)
- 30. U.S. Patent Publication No. US-2003-0004099-A1, published January 2 2003 (Eisenbach-Schwartz et al.);
- 31. U.S. Serial No. 09/359,099, filed July 22, 1999 (Strominger et al.);
- 32. U.S. Serial No. 09/487,793, filed January 20, 2000;
- 33. U.S. Serial No. 09/620,216, filed July 20, 2000;
- 34. U.S. Serial No. 09/765,301. Applicants point out that this reference is a counterpart of PCT International Application No. PCT/US01/02118 (WO 01/93893) (Item 54);

PGN. Ja

1 2/14/of

: Alexander Gad and Dora Lis

Serial No.

: Not Yet Known (Continuation of U.S. Serial

No. 09/816,989, filed March 32, 2001)

Filed

: Herewith

Page 32

35. U.S. Serial No. 09/765,644. Applicants point out that this reference is a counterpart of PCT International Application No. PCT/US01/02117 (WO 01/52878) (Item 52);

- 36. U.S. Serial No. 09/875,429, filed June 5, 2001 (Yong and Chabot);
- 37. U.S. Serial No. 09/885,227, filed June 20, 2001 (Rodriguez and Ure);
- 38. PCT International Application No. PCT/US88/02139 (WO 88/10120), published December 29, 1988 (Weiner et al.);
- 39. PCT International Application No. PCT/EP91/01420(WO 92/02543), published February 20, 1992 (Gaeta et al.);
- 40. PCT International Application No. PCT/US93/06249(WO 94/03484) published February 17, 1994 (McLean et al.).

 Applicants point out that this reference is a counterpart of U.S. Patent No. 5,623,052 (Item 8) and U.S. Patent No. 5,886,156 (Item 15);
- 41. PCT International Application No. PCT/US94/05632 (WO 94/26774), published November 24, 1994 (Alexander et al.);
- 42. PCT International Application No. PCT/US95/04121 (WO 95/26980), published October 12, 1995 (Hackett et al.);
- 43. PCT International Application No. PCT/US94/05697 (WO 95/31997), published November 30, 1995 (Reid et al.);

PS N. J

: Alexander Gad and Dora Lis

Serial No.

: Not Yet Known (Continuation of U.S. Serial

No. 09/816,989, filed March 32, 2001)

Filed Page 33 : Herewith

44. PCT International Application No. PCT/US95/06551 (WO 95/31990), published November 30, 1995 (Konfino et al.). Applicants point out that this reference is a counterpart of U.S. Patents Nos. 5,800,808 (Item 13) and 6,342,476 (Item 21);

- 45. PCT International Application No. PCT/EP95/02125 (WO 95/33475), published December 14, 1995 (Kotz et al.);
- 46. PCT International Application No. PCT/US98/00375 (WO 98/30227), published July 16, 1998 (Arnon et al.).

 Applicants point out that this reference is a counterpart of US Patent No. 6,214/791 (Item 20);
- 47. PCT International Application No. PCT/US99/16617 (WO 00/05249) published February 3, 2000 (Strominger et al). Applicants point out that this reference is a counterpart of U.S. Serial No. 09/359,099 (Item 31);
- 48. PCT International Application No. PCT/US99/16747 (WO 00/05250) published February 3, 2000 (Aharoni et al.);
- 49. PCT International Application No. PCT/US99/22402 (WO 00/18794) published April 6, 2000 (Gad, et al.). Applicants point out that this reference is a counterpart of U.S. Patent No. 6,514,938 (Item 23) and U.S. Patent Publication No. 20020115103 (Item 28);
- 50. PCT International Application No. PCT/US99/22836 (WO 00/20010) published April 13, 2000 (Flechter, et al.);

184 N. /2

: Alexander Gad and Dora Lis

: Herewith

Serial No.

: Not Yet Known (Continuation of U.S. Serial

No. 09/816,989, filed March 32, 2001)

Filed

Page 34

51. PCT International Application No. PCT/US99/27107 (WO 00/27417) published May 18, 2000 (Aharoni et al.);

- 52. PCT International Application No. PCT/US01/02117 (WO 01/52878), published July 26, 2001 (Eisenbach-Schwartz et al.);
- 53. PCT International Application No. PCT/US01/05198 (WO 01/60392)published August 23, 2001 (Gilbert et al.) Applicants point out that this reference is a counterpart of U.S. Patent Publication No. US-2001-0055568-A1 (Item 25);
- 54. PCT International Application No. PCT/US01/02118 (WO 01/93893), published December 13, 2001 (Eisenbach-Schwartz et al.);
- 55. PCT International Application No. PCT/US01/18248 (WO 01/93828) published December 13, 2001 (Yong and Chabot). Applicants point out that this reference is a counterpart of U.S. Serial No. 09/875,429 (Item 36);
- 56. PCT International Application No. PCT/US01/19649 (WO 01/97846) published December 27, 2001 (Rodriguez and Ure). Applicants point out that this reference is a counterpart of U.S. Serial No. 09/885,227 (Item 37);
- 57. European Patent Application No. 0 383 620 A2, published August 22, 1990 (Cook);
- 58. European Patent No. 0 359 783 B1, published November 29, 1995 (Werner, et al.);

189 N. J

: Alexander Gad and Dora Lis

Serial No.

: Not Yet Known (Continuation of U.S. Serial

No. 09/816,989, filed March 32, 2001)

Filed Page 35 : Herewith

59. Abramsky, et al., "Effect of a Synthetic Polypeptide (COP-1) on Patients with Multiple Sclerosis and with Acute Disseminated Encephalomyelitis", J. Neurol. Sci., 1977, 31, 433-438;

- 60. Aharoni, et al., "T Suppressor Hybridomas and Interleukin-2-Dependent Lines Induced by Copolymer 1 or by Spinal Cord Homogenate Down-Regulate Experimental Allergic Encephalomyelitis", Eur. J. Immunol., 1993, 23, 17-25;
- 61. Aharoni, et al., "Studies on the Mechanism and Specificity of the Effect of the Synthetic Random Copolymer GLAT on Graft-versis-Host Disease", Immunol.

 Letters, 1997, 58, 79-87;
- 62. Alvord, et al., "Myelin Basic Protein Treatment of Experimental Allergid Ensephalomyelitis in Monkeys", Ann. Neurol., 1979, 6, 469-473;
- 63. Arnon, et al., "Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Copolymer Immunological cross Reactive with Basic Encephalitogen", Israel J. Med. Sci., 1972, 8, 1759-1760;
- 64. Arnon, et al., "Suppression of EAE in Baboons by a Synthetic Bolymer of Amino Acids", Neurol., 1978, 28, 336 (Abstract);

py s. Ja

: Alexander Gad and Dora Lis

: Herewith

Serial No.

: Not Yet Known (Continuation of U.S. Serial

No. 09/816,989, filed March 32, 2001)

Filed

Page 36

65. Arnon, et al., "Desensitization of Experimental Allergic Encephalomyelitis with Synthetic Peptide Analogues" in Multiple Sclerosis (Academic Press, New York, 1980) 105-107;

- 66. Arnon, "A Synthetic Copolymer of Amino Acids in a Clinical Trial for MS Therapy" in Progress in Multiple Sclerosis Research (Bauer, Ritter, eds., Springer Verlag New York, 1980) 416-418;
- 67. Arnon, "Experimental Allergic Encephalomyelitis Susceptibility and Suppression", Immunological Rev., 1981, 55, 5-30;
- 68. Arnon, et al., "Suppression of Demyelinating Diseases by Synthetic Copolymers, in A Multidisciplinary Approach to Myelin Disease (G. Serlupi Crescenzi, ed., Plenum Publishing Corp., 1988) 243-250;
- 69. Arnon, et al., "Suppression of Experimental Allergic Encephalomyelitis by Cop-1 Relevance to Multiple Sclerosis", Israel J. Med. Sci., 1989, 25, 686-689;
- 70. Arnon, et al., "Immunomodulation of Experimental Allergic Encephalomyelitis", <u>Israel J. Med. Sci.</u>, 1993, 29, 175-181;
- 71. Arnon, et al., "On the Existence of Suppressor Cells",

 Int. Arch. Allergy Immunol., 1993, 100, 2-7;

PGN. Jan

: Alexander Gad and Dora Lis

Serial No.

: Not Yet Known (Continuation of U.S. Serial /

No. 09/816,989, filed March 32, 2001)

Filed : Herewith

Page 37

72. Arnon, et al., "Immunospecific Drug Design - Prospects for Treatment of Autoimmune Disease", Therapeutic Immunol., 1994, 1, 65-70;

- 73. Babu et al., "Reevaluation of response patterns of nonresponder mice to GLPhe polymers", Immunogen., 1983, 18(1): 97-100 (Abstract);
- 74. Babu et al., "Ir gene control of T and B Cell Responses to Determinants in (Glu Lys Ala) Terpolymer", J.

 Immunogenet., 1984, 11(3-4): 251-254;
- 75. Bansil, et al., "Multiple Sclerosis: Pathogenesis and Treatment", Seminars in Neurol., June 1994, 14(2), 146-153;
- 76. Baumhefner, et al., "Copolymer 1 as Therapy for Multiple Sclerosis: The Cons", Neurol., 1988, 38 (Suppl. 2), 69-71;
- 77. Baxevanis et al., "Genetic Control of T-Cell Proliferative Responses to Poly (Glu⁴⁰Ala⁶⁰) and Poly (Glu⁵¹Lys³⁴Tyr¹⁵): Subregion-Specific Inhibition of the Responses with Monoclonal Ia Antibodies", Immunogenetics, 1980, 11: 617-628;
- 78. Ben-Nun, et al., "The Autoimmune Reactivity to Myelin Oligodendrocyte Glycoprotein (MOG) in Multiple Sclerosis is Potentially Pathogenic: Effect of Copolymer 1 on MOG-induced Disease", J. Neurol., 1996, 243(Suppl. 1), S14-S22;

John J.

: Alexander Gad and Dora Lis

: Herewith

Serial No.

: Not Yet Known (Continuation of U.S. Serial

No. 09/816,989, filed March 32, 2001)

Filed Page 38

79. Bornstein, et al., "Treatment of Multiple Sclerosis with a Synthetic Polypeptide: Preliminary Results", Ann. Neurol., 1980, 8, 117 (Abstract);

- 80. Bornstein, et al., "Treatment of Multiple Sclerosis with a Synthetic Polypeptide: Preliminary Results", Trans. Am. Neurol. Assoc., 1980, 105, 348-350;
- 81. Bornstein, et al., "Multiple Sclerosis: Trial of a Synthetic Polypeptide", Ann. Neurol, 1982, 11, 317-319;
- 82. Brosnan, et al., "The Response of Normal Human Lymphocytes to Copolymer 1", J. Neuropath. Exp. Neurol., 1983, 42, 356 (Abstract);
- 83. Bornstein, et al., "Clinical Trials of Copolymer 1 in Multiple Sclerosis", Ann N.Y. Acad. Sci. (USA), 1984, 366-372;
- 84. Bornstein, et al., Clinical Trials of a Synthetic Polypeptide (Copolymer 1) for the Treatment of Multiple Sclerosis" in Gonsett et al., Immunological and Clinical Aspects of Multiple Sclerosis (MTP Press, The Hague, 1984) 144/150;
- 85. Bornstein, et/al., "Multiple Sclerosis: Clinical Trials of a Synthetic Polypeptide, Copolymer 1", Neurol., 1985, 35 (Suppl. 1), 103 (Abstract);

John N. Y

18/14/of

: Alexander Gad and Dora Lis

Serial No.

: Not Yet Known (Continuation of U.S. Serial

No. 09/816,989, filed March 32, 2001)

Filed Page 39

: Herewith

86. Bornstein, "Cop 1 May be Beneficial for Patients with Exacerbating-remitting Form of Multiple Sclerosis", Adv. Ther. (USA), 1987, 4, 206 (Abstract);

- 87. Bornstein, et al., "A Pilot Trial of Cop 1 in Exacerbating-remitting Multiple Sclerosis", New Eng. J. Med., 1987, 317(7), 408-414;
- 88. Bornstein, et al., "Clinical Experience with COP-1 in Multiple Sclerosis", Neurol., 1988, 38 Suppl. 2), 66-69;
- 89. Bornstein, et al., "Pilot Trial of COP-1 in Chronic Progressive Multiple Sclerosis: Preliminary Report", from The International Multiple Sclerosis Conference:

 An Update on Multiple Sclerosis, Roma (Italy), September 15-17, 1988, in Elsevier Science Publisher, 1989, 225-232;
- 90. Bornstein, et al., Clinical Trials of Cop 1 in Multiple Sclerosis" in Mandbook of Multiple Sclerosis (S.D. Cook Marcel Rekker, ed., 1990) 469-480;
- 91. Bornstein, et al., "A Placebo-controlled, Double-blind, Randomized Two-center, Pilot Trial of Cop 1 in Chronic Progressive Multiple Sclerosis", Neurol., 1991, 41, 533-539;
- 92. Bornstein, et al., "Treatment of Multiple Sclerosis with Copolymer 1" in <u>Treatment of Multiple Scleorsis:</u>

 Trial Design, Results and Future Perspectives (Rudick

Py N. J

: Alexander Gad and Dora Lis

Serial No.

: Not Yet Known (Continuation of U.S. Serial

No. 09/816,989, filed March 32, 2001)

Filed

: Herewith

Page 40

R.A. & Goodkin D.E., eds., Springer Verlag, London, 1992) 173-198;

- 93. Brosnan, et al., "Copolymer 1: Effect on Normal Human Lymphocytes", Ann. N.Y. Acad. Sci. (USA), 1984, 436, 498-499;
- 94. Brosnan, et al., "Immunogenic Potentials of Copolymer 1 in Normal Human Lymphocytes", Neurol., 1985, 35, 1754-1759;
- 95. Burns, et al., "Human Cellular Immune Response in Vitro to Copolymer)1 and Myelin Basic Protein (MBP)", Neurol., 1985, 35 (Suppl. 1) 170 (Abstract);
- 96. Burns, et al., "Human dellukar Immune Response to Copolymer 1 and Myelin Bisic Protein", Neurol., 1986, 36, 92-94;
- 97. Burns, et al., "Failure of Copolymer 1 to Inhibit the Human T-cell Response to Myelin Basic Protein", Neurol., 1991, 41, 131/1-1319;
- 98. Carter, et al., "Newer Drug Therapies for Multiple Sclerosis", Drug Therapy, 1990, 31-32, 37-39, 42-43;

707 s. J

: Alexander Gad and Dora Lis

Serial No.

: Not Yet Known (Continuation of U.S. Serial

No. 09/816,989, filed March 32, 2001)

Filed Page 41 : Herewith

- 99. Cazzato et al., "Treatment of Multiple Sclerosis. The Present and the Future. Study Group on Diagnosis and Therapy of Multiple Sclerosis", Database Medline on STN, Instituto do Clinica Neurologica, Universit`a, Trieste, Italy: Medline AN: 2000060325, Recent Progressi in Medicina, October 1999, 90(10): 538-544 (Abstract);
- 100. Clinical Trial Protocol No. 9001, Teva Pharmaceutical Industries, Ltd., first patient enrolled October 23, 1991);
- 101. Clinical Trial Protocol No. 9002, Lemmon Co. and Teva Pharmaceutical Industries, Ltd., first patient enrolled June 17, 1993;
- 102. Cohen, "Fundamental Immunology", Systemic Autoimmunity, 4th Ed., 1999, 1083:
- 103. The COP-1 Multicenter Clinical and Research Group Study, "COP-1 Multicenter Trial in Relapsing Remitting Multiple Sclerosis: 3 Year Follow Up", Abstracts of Symposia and Free Communication, Barcelona (Spain), June 25-29, 1994, 241 (Suppl. 1), 6;
- 104. Cotton, "Options for Multiple Sclerosis Therapy",

 J.A.M.A. Medical News & Perspectives, 1994, 272(18),

 1393;
- 105. Deeb et al., "Comparision of Freund's and Ribi adjuvants for inducing antibodies to the synthetic antigen (TG)-AL in rabbits", <u>J. Immunol. Methods</u>, 1992, 152(1): 105-113 (Abstract);

Pyv. J

: Alexander Gad and Dora Lis

Serial No.

: Not Yet Known (Continuation of U.S. Serial

No. 09/816,989, filed March 32, 2001)

Filed Page 42 : Herewith

106. De Kruyff et al., "Analysis of T Cell Responses to Poly-L (GluLys) at the Clonal Level. I. Presence of Responsive Clones in Nonresponder Mice", Eur. J. Immunol., 1987, 17 (8): 1115-1120 (Abstract);

- 107. Dorling, et al., "Prospects for Xenografting", <u>Curr.</u>

 <u>Opinions Immunol.</u>, 1994, <u>6</u>, 765-769;
- 108. Durelli, "Immunotherapeutics of Multiple Sclerosis",

 Instituto di Clinica delle Malattie del Sistema Nervoso

 Universita di Torino, 467-475;/
- 109. Falo et al., "Analysis of antigen presentation by metabolically inactive accessory cells and their isolated membranes", Proc Natl Acad. Sci. USA, 1985, 82(19): 6647-6651 (Abstract);
- 110. Ferrara, et al., "Graft-Versus-Host Disease", New Eng.

 <u>J. Med.</u>, 1991, <u>324</u>, 667-674;
- 111. Francis, "The Current Therapy of Multiple Sclerosis",

 J. Clin. Pharmacy and Therapeutics, 1993, 18, 77-84;
- 112. Fridkis-Hareli, et al., "Copolymer 1 Displaces MBP, PLP and MOG, but Can Not be Displaced by these Antigens from the MHC Class II Binding Site", Department of Chemical Immunology, The Weizmann Institute of Science, 1994;
- 113. Fridkis-Harel, et al., "Direct Binding of Myelin Basic Protein and Synthetic Copolymer 1 to Class II Major

189 s. Ja

: Alexander Gad and Dora Lis

Serial No.

: Not Yet Known (Continuation of U.S. Serial

No. 09/816,989, filed March 32, 2001)

Filed Page 43 : Herewith

Histocompatibility Complex Molecules on Living Antigen-Presenting Cells - Specificity and Promiscuity", Proc. Natl. Acad. Sci. USA, 1994, 91, 4872-4876;

- 114. Fridkis-Hareli, et al., "Specific and Promiscuous Binding of Synthetic Copolymer 1 to Class II Major Histocompatibility Complex Molecules on Living Antigen Presenting Cells", <u>Israeli Biochem. Soc.</u>, 1994, 21-22 (Abstract);
- 115. Fridkis-Hareli, et al., "Synthetic Copolymer 1 Inhibits theBinding of MBP, PLP and MOG Peptides to Class II Major Histocompatibility Complex Molecules on Antigen Presenting Cells" in Newtochem Mtg., August 14-19, 1994;
- 116. Fridkis-Hareli, et al., Synthetic Copolymer 1 Inhibits the Binding of MBP, PLF and MOG Peptides to Class II Major Histocompatibility Complex Molecules on Antigen-Presenting Cells", J. Neurochem., 1994, 63 (Suppl. I), 561;
- 117. Fridkis-Hareli, et al, "Synthetic Copolymer 1 and Myelin Basic Protein do not Require Processing Prior to Binding to Class II Major Histocompatibility Complex Molecules on Living Antigen Presenting Cells", Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot, Israel, 1994;
- 118. Fridkis-Hareli, et al., "Synthetic Copolymer 1 and Myelin Basic Protein Do Not Undergo Processing Prior to the Binding to Class II Major Histocompatibility

Pg v. Je

12/4/04

: Alexander Gad and Dora Lis

Serial No.

: Not Yet Known (Continuation of U.S. Serial

No. 09/816,989, filed March 32, 2001)

Filed Page 44 : Herewith

Complex Molecules on Antigen Presenting Cells", <u>Israeli</u> Immunol. Soc., May 3-4, 1994 (Abstract);

- 119. Fridkis-Hareli, et al., "Synthetic Copolymer 1 and Myelin Basic Protein Do Not Require Processing Prior to Binding to Class II Major Histocompatibility Complex Molecules on Living Antigen-Presenting Cells", Cell. Immunol., 1995, 163, 229-236;
- 120. Fridkis-Hareli, et al., "Promiscuous Binding of Synthetic Copolymer 1 to Purified HLA-DR Molecules", J. Immunol., 1998, 160, 4386-4397;
- 121. Fridkis-Hareli, et al., Synthetic Amino Acid Copolymers that Bind to HLA Dr. Proteins and Inhibit Type II Collagen-Reactive T Cell Clones", Proc. Natl. Acad. Sci., 1998, 95, 12528 12531;
- 122. Fridkis-Hareli et al., Rinding of random copolymers of three amino acids to class II MHC molecules", Intl. Immunol., 1999, 11(5): 635-641;
- 123. Fridkis-Hareli et al., Synthetic Peptides that Inhibit Binding of the Collagen Type II 261-273 Epitope to Arthritis-Associated HLA-DR1 and DR4 Rheumatoid Molecules and Collagen-Specific T-cell Responses", Database HCAPLUS /on STN, Department of Clinical Hospital, Aarhus, Immunology, Aarhus University HCAPLUS AN: 2000:455053, Human Immunology, Denmark, 2000, <u>61</u>(7): 640-650 (Abstract);
- 124. Grgacic, et/al., "Cell-mediated Immune Response to Copolymer / in Multiple Sclerosis Measured by the

John J

: Alexander Gad and Dora Lis

: Herewith

Serial No.

: Not Yet Known (Continuation of U.S. Serial

No. 09/816,989, filed March 32, 2001)

Filed

Page 45

Macrophage Procoagulant Activity Assay", <u>Int. Immurol.</u>, 1990, 2(8), 713-718;

- 125. Gurevich, "Study of the MHC-competition Between BP and Cop 1 Using Human Cytotoxic T-cell Clones" Israel J. Med. Sci., 1993 (Abstract);
- 126. Harrison and Hafler, "Antigen-Specific Therapy for Autoimmune Disease", Current Opin. Immunol., 2000, 12(6): 704-711;
- 127. Henry, Celia M., "Special Delivery", Chem. and Eng.
 News, Sept. 18, 2000, 49-54;
- 128. Herzenberg et al., "Lack of immune response gene control for induction of epitope-specific suppression by TGAL antigen", Nature, 1982, 295: 329-331 (Abstract);
- 129. Jacobs, et al., "Advances in Specific Therapy for Multiple Sclerosis", Meurol., 1994, 7, 250-254;
- 130. Johnson, "Clinical Studies in Copolymer 1 Therapy for Exacerbating-remitting Multiple Sclerosis", in Congress for Advances in the Understanding and Treatment of Multiple Sclerosis, Boston (USA), Oct. 28-29, 1992;
- 131. Johnson, "Experimental Therapy of Relapsing-Remitting Multiple Sclerosis with Copolymer-1", Ann. Neurol., 1994, 36(Suppl.), 115-117;

Poly N. Sp

: Alexander Gad and Dora Lis

: Herewith

Serial No.

: Not Yet Known (Continuation of U.S. Serial.

No. 09/816,989, filed March 32, 2001)

Filed

Page 46

132. Johnson, Management of Relapsing/Remitting Multiple Sclerosis with Copolymer 1 (Copaxone)", Chemical Abstracts, 1996, 125, 291993b;

- 133. Ju et al., "Idiotypic analysis of antibodies against the terpolymer L-glutamic acid 60-L-alanine30-L-tyrosine10 (GAT). IV. Induction of CGAT idiotype following immunization with various synthetic polymers containing glutamic acid and tyrosine", <u>Eur. J.</u> Immunol., 1979, 9(7): 553-560 (Abstract);
- 134. Kay, et al., "The Mechanism of Action of FK 506",

 Transplantation Proceedings, 1990, 22(1, Suppl. 1), 9699;
- 135. Keith, et al., "The Effect of COP 1, a Synthetic Polypeptide, on Chronic Relapsing Experimental Allergic Encephalomyelitis in Cuinea Pigs" J. Neurol. Sci., 1979, 42, 267-274;
- 136. Keleman, et al., "Graft-versus-Host Disease in Bone Marrow Transplantation: Experimental, Laboratory, and Clinical Contributions of the Last Few Years", Int. Arch. Allergy Immunol., 1993, 102, 309-320;
- 137. Kepsutlu et al., "Evaluation of Chitosan Used as an Excipient in Tablet Formulations", Database HCAPLUS on STN, Department of Pharmaceutical Technology, Gulhane Military Medical Academy, Ankara, 06018, Turkey, HCAPLUS AN: 1999: 590411, Acta. Pol. Pharm. 1999, 56(3): 27-235 (Abstract);

789 J. J

Applicants : Alexander Gad and Dora Lis

Serial No. : Not Yet Known (Continuation of U.S. Serial)

No. 09/816,989, filed March 32, 2001)

Filed : Herewith

Page 47

138. Kott, et al., "COP-1 Increases Suppressor Cells Number in Multiple Sclerosis", <u>Israel Neurological Assoc.</u>, December 19-20, 1994, Herzliya (Israel), 17;

- 139. Kropshofer et al., "Self-Peptides from Four HLA-DR Alleles Share Hydrophobic Anchor Residues Near the NH₂-Terminal Including Proline as a Stop Signal for Trimming", J. Immunol., 1993, 151: 4/32-4742;
- 140. Lai et al., "Complementation of Class II A alleles in the immune response to (GluLysTyr) polymers", Exp. Clin. Immunogenet., 1986 3(1): 38-48 (Abstract);
- 141. Lai et al., "Monoclonal T cell responses to two epitopes on a single immunogen controlled by two distinct genes", J. Immunol., 1986, 136(10): 3799-3804 (Abstract);
- 142. Lando, et al., "Effect of Cyclophosphamide on Suppressor Cell Activity in Mice Unresponsive to EAE", J. Immunol., 1979, 123, 2156-2160 (Abstract);
- 143. Lando, et al., "Experimental Allergic Encephalomyelitis in Mice Suppression and Prevention with COP-1", Israel J. Med. Sci., 1979, 15, 868-869 (Abstract);
- 144. Lee, et/al., "Peptide and Protein Drug Delivery" in

 Advances in Parenteral Sciences (Vincent H.L. Lee, ed.,

 Marcel Dekker, Inc., 1990) 691-695;

Poly N. J.

1 2/14/of

: Alexander Gad and Dora Lis

Serial No.

: Not Yet Known (Continuation of U.S. Serial/

No. 09/816,989, filed March 32, 2001)

Filed

: Herewith

Page 48

145. Li et al., "Glatiramer acetate blocks the activation of THP-1 cells by interferon-γ", Eur. J. Pharmacol.,/1998, 342: 303-310;

- 146. Lisak, et al., "Effect of Treatment with Copolymer 1 (Cop-1) on the in Vivo and in Vitro Manifestations of Experimental Allergic Encephalomyelitis/ (EAE)", J. Neurol. <u>Sci.</u>, 1983, <u>62</u>, 281-293;
- 147. Matsunaga et al., "Complementation of Class II A alleles in the immune response / to (Glu-Lys-Tyr) polymers", Yokohama Med. Bull., /1988, 39(1-2): 9-19 (Abstract);
- 148. Maurer et al., "Interpretations of immune responses of mice to poly(Glu60Lys40) tts/modified derivatives, and the terpolymers poly (Tu55Lys37Leu8) (Glu56Lys37Ser7)", Clin, Immunopathol., 1980, 15(3): 344-356 (Abstract);
- 149. McDermott, et al., "Antigen-induced Suppression of Experimental Allergic Neuritis in the Guinea Pig", J. Neurol. Sci., 1980, 46, 137-143;
- Trial "COP-1 / Multicenter Clinical in 150. Meiner, Exacerbating-remitting Multiple-Sclerosis: One Follow-up", J. Neurol., 1991(Suppl. 1) (Abstract);
- 151. Meiner, et al/, "The Israeli COP-1 Multicenter Clinical Trial in Exacerbating-remitting Multiple Sclerosis -Two-year Follow-up", in 9th Congress of the European Committee / for Treatment and Research in Multiple

: Alexander Gad and Dora Lis

Serial No.

: Not Yet Known (Continuation of U.S. Serial

No. 09/816,989, filed March 32, 2001)

Filed

: Herewith

Page 49

Sclerosis, Florence (Italy), October-November, 1993 48 (Abstract);

- 152. Mengle-Gaw, "The Major Histocompatibility Complex (MHC)", in Encycl. Molecular Bio. (Oxford Blackwell Science Ltd, 1994) 602-606;
- 153. Milo, et al., "Inhibition of Myelin Basic Protein-specific Human T-cell Lines by COP-1", Israel J. Med. Sci., 1992, 28, 486 (Abstract);
- MHC Expression and Cytokine Synthesis in the THP-1

 Monocyte-Macrophage Cell Line (USA), December 10, 1993

 (Abstract);
- 155. Milo, et al., "Additive Effects of COP-1 and IFN-Beta on Immune Responses to Myelin Basic Protein", Neurol., 1994, 44 (Suppl. 2), A212;
- 156. Milo, et al., "Additive Effect of Copolymer-1 and Interferon-β on the Immune Response to Myelin Basic Protein", Assaf Harofeh Medical Center, Sackler School of Medicine, Tel-Aviv University of Maryland School of Medicine, 1994, 22;
- 157. Milo, et al., "Copolymer-1 and Interferon-β Additively Suppress the Immune Response to Myelin Basic Protein by Inhibiting Antigen Presentation", J. Neuroimmunol., 1994, 54, 188 (Abstract);

Jog de Ye

: Alexander Gad and Dora Lis

: Herewith

Serial No.

: Not Yet Known (Continuation of U.S. Serial

No. 09/816,989, filed March 32, 2001)

Filed

Page 50

158. Milo, et al., "Additive Effects of Copolymer-1 and Interferon β-1b on the Immune Response to Myelin Basic Protein", J. Neuroimmunol., 1995, 61, 185-193;

- 159. Myers, et al., "The Peculiar Difficulties of Therapeutic Trials for Multiple Sclerosis", Neurologic Clinics, 1990, 8(1), 119-141;
- 160. Nightingale, et al., "Access to Investigational Drugs for Treatment Purposes", Am. Family Physician, 1994, 50(4), 845-847;
- of Pharmacy, Remington, 1996 2, 1598-1614;
- 162. Pender, et al., Internal Med. Journal, 2002, 32: 554-563;
- 163. Porter, "Coating of Pharmaceutical Dosage Forms," in The Science and Practice of Pharmacy, Remington, 1995, 2, 1650-1659;
- 164. Prat et al., "Lymphocyte Migration and Multiple Sclerosis: Relation with Disease Course and Therapy,"

 Ann. Neurol., 1999, 46: 253-256;
- 165. Puri et al., "Modulation of the Immune Response in Multiple Sclerosis", J. Immunol., 1997, 158, 2471-2476;
- 166. Racke, et al., "Copolymer-1-induced Inhibition of Antigen-specific T Cell Activation: Interference with

Pgs. Je

12/14/of

: Alexander Gad and Dora Lis

Serial No.

: Not Yet Known (Continuation of U.S. Serial

No. 09/816,989, filed March 32, 2001)

Filed

: Herewith

Page 51

Antigen Presentation", J. Neuroimmunol., 1992, 37, 75-84;

- 167. Reilly, Jr., W.J., "Pharmaceutical Necessities" in The Science and Practice of Pharmacy, Remington 1995, 2, 1380-1416;
- 168. Rolak, "Copolymer-I Therapy for Multiple Sclerosis", Clin. Neuropharmacology, 1987, 10(5), 389-396;
- 169. Rothbard, et al., "Interactions Between Immunogenic Peptides and MHC Proteins", Ann. Rev. Immunol., 1991, 9, 527-565;
- 170. Salvetti, et al., "Myelin Basic Protein T Cell Epitopes in Patients with Multiple Sclerosis", Department of Neurological Sciences, University of Rome, La Sapienza 1991, 72 (Abstract);
- 171. Schlegel, et al., "Prevention of Graft-Versus-Host Disease by Peptides Binding to Class II Major Histocompatibility Complex Molecules", Blood, 1994, 84(8), 2802-2810;
- 172. Schlegel, et al., "Inhibition of Allorecognition and Prevention of Graft-vs-host Disease (GVHD) by GLAT, a Synthetic Polymer with Promiscuous Binding to Murine and Human MHC Class II Molecules", in Am. Soc.

 Hematology, 37th Annual Meeting, Seattle, WA (USA), December 1/5, 1995, 224a (Abstract);

Toly N. F

12/4/04

: Alexander Gad and Dora Lis

Serial No.

: Not Yet Known (Continuation of U.S. Serial

No. 09/816,989, filed March 32, 2001)

Filed Page 52 : Herewith

- 173. Schwartz et al., "Gene complementation in the T /poly lymphocyte proliferative response (Glu57Lys38Tyr5): Evidence for effects of polymer handling and gene dosage", J. Immunol., 1979, 123(1): 272-278 (Abstract);
- 174. Sela, et al., "Experimental Allergic Encophalomyelitis" in Menarini Series on Immunopathology/vol. 1, First Symposium of Organ Specific Autoimmunity", Cremona, Italy, June, 1977, (Miescher P.A./ed., Schwabe Co., Basel, 1978), 9-21;
- 175. Sela, et al., "Suppressive Agrivity of COP-1 in EAE and its Relevance to Multiple Sclerosis", Bull. Inst. Pasteur, 1990, 88, 303-314;
- as Immunomodulatory Vaccines 176. Sela, "Polymeric Drugs, Against Multiple Sclerøsis", Makromol. Chem. Macromol. Symp., 1993, 70/71, 147-155;
- Transplantation Proceedings, 22 (1, 1990, 177. Starzl, Suppl. 1), 5;
- 178. Stark, "Expanded Clinical Trials of Treatments for Multiple Sclerosis (MS): Copolymer 1 (COP-1) Treatment Investigational New Drug (IND) Program", Ann. Neurol., 1994, 36, /114-115;
- 179. Sykes, / Immunobiology of Transplantation", Faseb J., 1996, <u>10</u>, 721-730;

: Alexander Gad and Dora Lis

Serial No.

: Not Yet Known (Continuation of U.S. Serial

No. 09/816,989, filed March 32, 2001)

Filed Page 53 : Herewith

180. Tarcic et al., "Copolymer 1 (Copaxone) from an Idea to a Drug for Treatment of Multiple Sclerosis" Database HCAPLUS on STN, Israel: AN 1997:333270. Kim, Handasa

Kim, 1997, 281(14), 16-18 (Abstract);

181. Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Polypeptide",

Eur. J. Immunol., 1971, 1, 242-248;

182. Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis by a Synthetic Polypeptide",

Israel J. Med. Sci., 1971, 7 630-631 (Abstract);

183. Teitelbaum, et al., "Protection Against Experimental Allergic Encephalomyelitis", Nature, 1972, 240, 564-

566;

184. Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis with Basic Polymers", <u>Eur.</u>

<u>J. Immunol.</u>, 1973, <u>3</u>, 273-279;

185. Teitelbaum, et al., "Dose-response Studies on Experimental Allergic Encephalomyelitis Suppression by

COP-1", <u>Israel J./Med. Sci.</u>, 1974, <u>10</u>(9), 1172-1173;

186. Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis in Rhesus Monkeys by a Synthetic Basic Copolymer", Clin. Immunol. Immunopath.,

1974, 3, 256-262;

pgs. Je

: Alexander Gad and Dora Lis

Serial No.

: Not Yet Known (Continuation of U.S. Serial

No. 09/816,989, filed March 32, 2001)

Filed

: Herewith

Page 54

187. Teitelbaum, et al., "Suppression of Experimental Allergic Encephalomyelitis in Baboons by Cop 1", <u>Israel</u> <u>J. Med. Sci.</u>, 1977, <u>13</u>, 1038 (Abstract);

- 188. Teitelbaum, et al., "Blocking of Sensitization to Encephalitogenic Basic Protein in Vitro by Synthetic Basic Copolymer (COP 1)" in Cell Biology and Immunology of Leukocyte Function (Academic Press, New York, 1979) 681-685;
- 189. Teitelbaum, "Suppression of Experimental Allergic Encephalomyelitis with Synthetic Copolymer Relevance to Multiple Sclerosis", in <u>Humoral Immunity in Neurological Diseases</u> (Karcher D., Lowenthal A. & Strosberg A.D., eds., Plenum Publishing Corp., 1979) 609-613;
- 190. Teitelbaum, et al., "Monoclonal Antibodies to Myelin Basic Protein Cross React with Synthetic EAE-suppressive Copolymer, COP 1" in Proc. 7th Eur. Immunol.

 Mtg., Jerusalem, September 8-13, 1985 (Abstract);
- 191. Teitelbaum, et al., "Specific Inhibition of the T-cell Response to Myelin Basic Protein by the Synthetic Copolymer Cop 1", Proc. Natl. Acad. Sci. USA, 1988, 85, 9724-9728;
- 192. Teitelbaum, et al., "Clinical Trial of Copolymer 1 in Multiple Sclerosis" <u>J. Israel Med. Assoc.</u>, 1989, <u>CXVI</u>(9), 453-456;

John J.

: Alexander Gad and Dora Lis

Serial No.

: Not Yet Known (Continuation of U.S. Serial

No. 09/816,989, filed March 32, 2001)

Filed Page 55

: Herewith

of Monoclonal Antibodies Against Myelin Basic Protein and Against the Synthetic Copolymer 1", Proc. Natl. Acad. Sci. (USA), 1991, 88, 9528-9532;

- 194. Teitelbaum, et al., "Synthetic Copolymer 1/Inhibits Human T-cell Lines Specific for Myelin Basic Protein", Proc. Natl. Acad. Sci. (USA), 1992, 89, 137/141;
- 195. Teitelbaum, et al., "Immunological Parameters in a Multicenter Clinical Trial of COP1 in Multiple Sclerosis (MS): A 2-year Follow-up", Neurol., 1994, 44 (Suppl. 2), A358;
- 196. Teitelbaum, et al., "Copolimer 1 Inhibits Chronic Relapsing Experimental Allergic Encephalomyelitis Induced by Proteolipid Protein (PLP) Peptides in Mice and Interferes with PLP specific T Cell Responses", J. Neuroimmunol., 1996, 64, 209-217;
- 197. Teitelbaum, et al., "Copolymer 1 from the Laboratory to FDA", <u>Israel J. Med. Sci.</u>, 1997, <u>33</u>, 280-284;
- 198. Thompson, "MCQ Tutor: Medical Immunology Multiple Choice Questions", Immunol. Today, 1985, 6(4), 141;
- 199. Tisch et al., "Antigen-specific immunotherapy: Is it a Real Possibility to Combat T-Cell-Mediated autoimmunity?" Proc. Natl. Acad. Sci. U.S.A., 1994, 91, 437-438;

Phy M. Agr

: Alexander Gad and Dora Lis

Serial No.

: Not Yet Known (Continuation of U.S. Serial

No. 09/816,989, filed March 32, 2001)

Filed

: Herewith

Page 56

200. Trannoy et al., "Epitope-specific regulation of the T cell repertoire: carrier recognition in association with I-E or I-A does not influence the restriction of hapten-specific T cells", <u>Eur. J. Immunol</u>. 1985, 15(12): 1215-1221 (Abstract);

- 201. Van den Bogaerde, et al., "Induction of Long-Term Survival of Hamster Heart Xenografts in Rats", Transplantation, 1991, 52, 15-20;
- 202. Van Noort, et al., International Review of Cytology, 1996, 178: 127-205;
- 203. Webb, et al., "Further Studies on the Suppression of Experimental Allergic Encephalomyelitis by Synthetic Copolymer", <u>Israel J. Med. Sci.</u>, 1972, <u>8</u>, 656-657;
- 204. Wender, "Copolymer 1 (COP-1) in the Treatment of Multiple Sclerosis (Letter)" Neur. Neurochir. Pol., 1990, 24, 113;
- 205. Weinshenker, et al., "Natural History and Treatment of Multiple Sclerosis", <u>Current Opinion in Neurol. and Neurosurgery</u>, 1992, <u>5</u>, 203-211;
 - 206. Webb, et al., "In Vivo and in Vitro Immunological Cross-reactions between Basic Encephalitogen and Synthetic Basic Polypeptides Capable of Suppressing Experimental Allergic Encephalomyelitis", <u>Eur. J. Immunol.</u>, 1973, 3, 279-286;

pgs. J

18/4/04

Applicants : Alexander Gad and Dora Lis

Serial No.

: Not Yet Known (Continuation of U.S. Serial

No. 09/816,989, filed March 32, 2001)

Filed

: Herewith

Page 57

- 207. Webb, et al., "Suppression of Experimental Allergic Encephalomyelitis in Rhesus Monkeys by a Synthetic Basic Copolymer", Isr. J. Med. Sci., 1975, /11, 1388 (Abstract);
- 208. Webb, et al., "Molecular Requirements/ Involved in Suppression of EAE by Synthetic Basiq Copolymers of Amino Acids", Immunochem., 1976, 13, 3/3-337;
- 209. Webster's II New Riverside University Dictionary, definition of "preventing", /The/Riverside Publishing Co., 1984, page 933;
- 210. Winer, "COP 1 Therapy for Multiple Sclerosis", New Eng. J. Med., 1987, 317(7), 42,444;
- 211. Zisman et al., "Dichotomy between the T and the B cellepitopes of the winthetic polypeptide (T,G)-A--L", Eur. J. Immunol., 1994, 24(10): 2497-2505 (Abstract); and
- 212. Zisman et al./ "Direct binding of a synthetic Major Class II to multichain polypeptide Histocompatibility Complex molecules on Antigen-Presenting gells and stimulation of a specific T-cell line require processing of the polypeptide", Proc. 9732-9742 Acad. Sci. USA, 1991, 88(21): Natl. (Abstract).

Applicants request that the Examiner review the publications and make them of record in the subject application.